title: Re: Claus G. Roehrborn, Steven A. Kaplan, J. Stephen Jones, Joseph T. Wang, Tamara Bavendam, Zhonghong Guan. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009;55:472-81.
authors: Shiu-Dong
authors: SD
authors: Chung
authors: Bin
authors: B
authors: Chiu
authors: Yao-Chi
authors: YC
authors: Chuang
authors: Hann-Chorng
authors: HC
authors: Kuo
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D002114:Calcinosis / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000033:anatomy & histology*; D011469:Prostatic Diseases / Q000473:pathology; D011472:Prostatitis / Q000175:diagnosis / Q000503:physiopathology; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014570:Urologic Diseases / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin